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Purpose. To determine association between apparent diffusion coefficient value on diffusion-weighted imaging and Gleason score
in patients with prostate cancer. Methods. This retrospective case series was conducted at Radiology Department of Aga Khan
University between June 2009 and June 2011. 28 patients with biopsy-proven prostate cancer were included who underwent
ultrasound guided sextant prostate biopsy and MRI. MRI images were analyzed on diagnostic console and regions of interest
were drawn. Data were entered and analyzed on SPSS 20.0. ADC values were compared with Gleason score using one-way
ANOVA test. Results. In 28 patients, 168 quadrants were biopsied and 106 quadrants were positive for malignancy. 89 lesions
with proven malignancy showed diffusion restriction. The mean ADC value for disease with a Gleason score of 6 was 935mm2/s
(SD = 248.4mm2/s); Gleason score of 7 was 837mm2/s (SD = 208.5mm2/s); Gleason score of 8 was 614mm2/s (SD = 108mm2/s);
and Gleason score of 9 was 571mm2/s (SD = 82mm2/s). Inverse relationship was observed between Gleason score and mean
ADC values. Conclusion. DWI and specifically quantitative ADC values may help differentiate between low-risk (Gleason score,
6), intermediate-risk (Gleason score, 7), and high-risk (Gleason score 8 and 9) prostate cancers, indirectly determining the
aggressiveness of the disease.
1. Introduction
Carcinoma of the prostate is a significant health issue affect-
ing predominantly elderly men. In the year 2012 in United
States of America (USA), estimated new cases and deaths
from prostate cancer are 241,740 and 28,170 respectively [1].
Worldwide prostate cancer ranks third in cancer incidence
and sixth in cancermortality.The incidence of prostate cancer
is not high in Pakistan, with an estimated figure of 3/100,000
of population. The possible explanation for this is lower
life expectancy and no established screening programme for
prostate cancer in Pakistan [2].
Thediagnosis of prostate cancer is based on a digital rectal
examination (DRE) and assessment of serumprostate specific
antigen (PSA) followed by transrectal ultrasound (TRUS)-
guided biopsy.
Magnetic resonance imaging (MRI) of prostate cancer
with conventional T2-weighted imaging is routinely used
for diagnosis and local staging of prostate cancer along
with biopsy. The presence of extra capsular extension and
seminal vesicle invasion are sought.However, themore recent
application of functional MRI, including diffusion-weighted
imaging (DWI), MR spectroscopy, and dynamic contrast
enhanced MR, has strong potential to expand the role
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Table 1: Comparison of ADC values with previous studies.
Low-risk adenocarcinoma
mean ADCmm2/s
Moderate risk adenocarcinoma
mean ADCmm2/s
High-risk adenocarcinoma
mean ADCmm2/s
Yoshimitsu et al. [13] 1.19 × 10−3 1.10 × 10−3 0.93 × 10−3
Woodfield et al. [14] 0.86 × 10−3 0.702 × 10−3 0.68 × 10−3
Yaǧci et al. [15] 1.18 × 10−3 1.05 × 10−3 0.84 × 10−3
Shayan et al.a 0.93 × 10−3 0.83 × 10−3 0.57 × 10−3
aCurrent study results.
of MRI by noninvasive characterization of prostate cancer
and providing more accurate information regarding tumor
location, size, spread, and aggressiveness [3, 4].
Several studies have recently shown that DWI can help
differentiate between benign and malignant prostatic tissue
on the basis of lower apparent diffusion coefficient (ADC)
values of prostate carcinoma in comparison with normal
prostate tissue.The reportedADCvalues of prostate cancer in
the peripheral zone range between 0.98 and 1.45× 10−3mm2/s
[3, 5–10].
The histopathology reference standard formeasuring and
reporting prostate cancer aggressiveness is the Gleason grad-
ing system. Gleason grades 1–5 correspond to progressively
more poorly differentiated prostate cancer. A given tumor is
assigned both a primary (most prevalent) and a secondary
(second most prevalent) Gleason grade, and the sum of these
grades yields the Gleason score (GS). Gleason scores are also
used to describe tumors as low grade (Gleason score ≤ 6),
intermediate grade (Gleason score 7), or high grade (Gleason
score > 7) with respect to tumor aggressiveness [11].
The Gleason score decides the biological and prognostic
behavior of the prostate tumor, achieved on transrectal
biopsy or radical prostatectomy specimen. Accurate scoring
is critical in decision of appropriate therapy in order to benefit
the patient most, according to the risk stratification. For low-
risk tumors (Gleason score < 7) no immediate treatment
is required, that is, watchful waiting. For intermediate-risk
(Gleason score = 7) monotherapy is offered and for high-risk
prostate cancer (Gleason score > 7) combination therapy will
be the best treatment option [12].There is a dearth of scientific
literature regarding utility of functional MRI in predicting
tumor biology and behavior from south-east Asia. Therefore,
we attempted to compareDWI andADC values withGleason
score to determine the relationship between the two and
explore new pathway for noninvasive assessment of tumor
aggressiveness. Comparison of Mean ADC values with prior
studies is given in Table 1.
2. Materials and Methods
2.1. Overview. A descriptive case series was conducted at
the Radiology Department of Aga Khan University Hospital
between June 2009 and June 2011. Data were retrospectively
retrieved from the medical record system. The institutional
ethical review committee granted exemption for patients’
informed consent because data was retrospectively retrieved.
As per departmental protocol, every contrast-enhanced study
is performed after a written informed consent.
2.2. Study Population. Study sample consisted of 28 patients
proved to have prostatic malignancy on basis of ultrasound
guided sextant prostate biopsy at our department and later
underwent MRI of pelvis for staging of disease. Patients were
excluded if they had undergone prior surgery, radiotherapy,
or hormonal therapy and contra-indications to MR imaging.
In addition, patients were excluded if their biopsy was per-
formed outside our institution. They were enrolled via non-
probability purposive technique. Each patient underwent
sextant biopsy and out of 28 patients total 168 biopsy samples
were obtained. The 6 quadrants of prostate on MR imaging
were taken as individual sample and analyzed.
2.3. Biopsy Technique. All biopsies were performed by cre-
dentialed radiologists using the same standard technique and
18-gauge core biopsy needles. Right and left half of each
prostate gland was divided into a total of 6 zones (apex, mid,
and base on each side). One core biopsy sample was obtained
from each zone. Informed consent is taken by every patient
in undergoing biopsy in our institution.
2.4. Imaging Protocol. All MRI scans were performed with
1.5 T machine (MagnetomAvanto, Siemens) using pelvic
phased array coil. MRI pelvis protocol included sagittal, axial
and coronal turbo spin echo T2-weighted images, coronal
turbo spin echo T1-weighted images, axial turbo spin echo
T1-weighted fat suppressed images, diffusion weighted axial
images (𝑏-value 50, 400, and 800 s/mm2) withADCmaps and
post contrast fat suppressed sagittal, and coronal and axial T1-
weighted images.
2.5. Image Analysis and Reader Procedure. Images were
reviewed by 3 years’ experienced radiologist trained in MRI
and a senior resident on diagnostic workstation. All regions
of interest (ROIs) were drawn on ADC maps with consensus
and in case of difference in opinion; final judgment was taken
from the third radiologist with 7 years’ experience in MRI
reporting. Assessment was based on 6 anatomical zones of
prostate peripheral zone. The readers were aware of patient’s
prostatic malignancy but blinded to biopsy reports. Quanti-
tative values of ADCwere obtained from each quadrant by all
three readers.
2.6. Data Analysis Plan. Data was entered and analyzed in
SPSS 20.0 version. Proportions and mean ADC values of
each Gleason score were calculated individually along with
standard deviation. Range was also computed. Shapiro-Wilk
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Table 2: Number of diffusion positive and negative quadrants
according to the sextant based prostate biopsy results.
Gleason scores Diffusion positivequadrants
Diffusion negative
quadrants
6 35 13
7 28 4
8 10 0
9 16 0
Total 89 17
test of normality was assessed as a numerical means for
testing normality at 𝑝 value > 0.05. A one-way between and
within subjects analysis of variance (ANOVA)was conducted
to compare the effect of ADC values on aggressiveness of
tumor as predicted by Gleason score. 𝑝 value < 0.05 will be
taken as statistically significant. Tukey’s post hoc analysis was
computed to assess statistically significant difference among
various levels of Gleason scores. (Such as low grade from
intermediate and high grade and multiple comparisons).The
6 quadrants of each patient were analyzed individually and
interrelated with Gleason scores derived from histopatholog-
ical results.
3. Results
In our study, 28 men (mean age, 69.6 years ± SD 7.8; range,
53–88 years) underwent a total of 168 transrectal ultrasound-
guided core biopsy of prostate. Sixty-three percent, that is,
107/168 of these sextant biopsies, were found to have prostate
cancer. All Transrectal ultrasound-guided biopsies and sites
of tumor were in the peripheral zone of the prostate gland.
Twenty-eight tumors were identified in apex, 40 in mid zone,
and 39 present in base. Twenty-six subjects (92%) had more
than one quadrant involved by tumor on sextant biopsy
and only two subjects had single site of involvement. In
one patient, single quadrant from left lobe yielded tumor;
however the sample was inadequate and Gleason score could
not be calculated. The mean PSA level was 44.5 ng/mL ± SD,
78.5, range 1.1–395.6 ng/mL.
No special consideration was given to areas showing
hemorrhage; however the number of quadrants involved was
recorded. T2-weighted images for tumor assessment were not
statistically evaluated.
3.1. MRI Imaging. The mean number of days between tran-
srectal ultrasound-guided prostate biopsy and MRI was 14 ±
SD 9 days, range 2–40 days. Ample number of biopsy-proven
sites of prostate cancer was not detected on DWI. Eighty-
nine (84%) biopsy-proven sites of prostate carcinoma were
diffusion restricted. The remaining 17 (16%) biopsy-proven
sites of cancer were not visible on DWI. The Gleason scores
for the 89 quadrants visible and 17 quadrants not visible on
DWI are given in (Table 2).
Total of 17 quadrants were not visible on DWI and these
entire quadrants positive for tumor had Gleason scores of 6
and 7. Hence, we saw that the lower the Gleason score, the
less densely packed the tumor and therefore less diffusion
restriction of the water molecules. This hypothesis was
supported by the means’ plot showing inverse relationship
between ADC values and tumor aggressiveness (Figure 1).
Significant negative relationship was identified betweenADC
values in PZ cancer and tumor Gleason score.
For the 89 tumors visible on DWI, the mean ADC values
± SD were 803 ± 246mm2/s, range: 452–1450mm2/s. The
radiologist observed variation and overlap in ADC value
among the different groups (Figure 2).Themean ADC values
of Gleason scores 6–9, visible on DWI are given in (Table 2).
In 56/168 (33.3%) quadrants proven to be benign prostatic
tissue on biopsy had no diffusion restriction. Hemorrhage
was observed in 10 quadrants which were of variable intensity
on T1 and T2.ThemeanADC value for the 56 cases of benign
prostatic tissue was 1346mm2/s ± 309mm2/s, range: 2101–
1011mm2/s.
A one-way ANOVA was conducted between means of
ADC values to compare relationship of ADC value with
tumor aggressiveness, such as, low grade (Gleason score 6),
intermediate grade (Gleason score 7), and high grade (Glea-
son scores 8 and 9) tumors. There was a highly significant
effect of tumor aggressiveness on ADC values taken at 𝑝 <
0.05 for various levels of Gleason scores. (𝐹(3, 85) = 15.2;
𝑝 < 0.0001). Post hoc comparisons using Tukey’s HSD test
indicated that the mean ADC value for low grade tumors
(𝑀 = 935.8mm2/s, SD = 248.4mm2/s) was significantly
different than high grade tumors (𝑀 = 614.1mm2/s, SD =
108mm2/s) (𝑀 = 571.9mm2/s, SD = 82mm2/s). However,
the intermediate grade tumor (𝑀 = 837.2mm2/s, SD =
208.5mm2/s) did not significantly differ from low grade
but differed from high grade tumors. Taken together, these
results suggest that tumor aggressiveness has strong inverse
relationship with ADC value. Specifically, our results suggest
that the more aggressive the tumor the lesser the ADC value.
However, it should be noted that low grade and intermediate
grade tumors have no statistically significant difference in
ADC values. Imaging of two cases has been illustrated in the
paper as Figures 3 and 4.
4. Discussion
Diffusion restriction in prostate cancer with corresponding
signal drop outs onADCmapping has beenwell documented
in multiple prior studies [5, 6, 9, 16–19].
The pathophysiology behind these signals is increased
water proton in rapidly growing tumor cells in extracellular as
well as intracellular environmentwhich have restrictedmove-
ments and therefore give reduced ADC values compared to
the normal healthy prostatic tissue [20–23].
Significant reduction in diffusion restriction and low
ADC values in prostate cancer have been well established
and few prior studies have studied the relationship between
prostate cancer ADC value and aggressiveness. No such study
has been performed in our population on this subject to date.
Our study gives some interesting results which correlateswith
prior investigations.
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ADC values
Mean Std. deviation Std. error
95% confidence interval for mean
Lower bound Upper bound
6 35 935.83 248.377 41.983 850.51 1021.15
7 28 837.18 208.487 39.400 756.34 918.02
8 10 614.10 107.952 34.137 536.88 691.32
9 16 571.88 82.017 20.504 528.17 615.58
Total 89 803.21 246.306 26.108 751.33 855.10
N
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Figure 1: Means plot-inverse relationship between ADC values and Gleason score.
ADC values
Minimum Maximum
6 542 1450
7 465 1236
8 479 785
9 452 731
Total 452 1450
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Figure 2: Scatter plot showing the relationship betweenADC values
in PZ cancers and Gleason scores.
In our observation of comparison between tumor aggres-
siveness and diffusion characteristics, we discovered inverse
relationship between Gleason score and ADC values. There
is an increase in Gleason score with falling ADC values.
Considering tumor visibility on diffusion weighted images,
their corresponding ADC values helped us to differentiate
between low-risk (i.e., Gleason score 6) and high-risk (i.e.,
Gleason scores 8 or 9) prostate cancer (𝑝 < 0.0001) and
between intermediate-risk (i.e., Gleason score 7) and high-
risk (i.e., Gleason score 8 and 9) prostate cancer (𝑝 = 0.019
and 𝑝 < 0.0001). Differentiation between low-risk (i.e.,
Gleason score 6) and intermediate-risk (i.e., Gleason score 7)
prostate cancer was found insignificant (𝑝 = 0.226) which
may be explained by the fact that there is less variability
between their cell density and composition.
Arora et al. have concluded that prostate adenocarci-
nomas if multifocal have variable Gleason scores based on
heterogeneity and this leads to difference between individual
tumor focus Gleason score and overall Gleason score [24].
Similarly the cellular density is also variable with each
focus and leads to overlap in the ADC value. Considering
this overlap in the ADC value and retrospective nature of the
study, we found that ADC value alone is not a good predictor
of Gleason score and aggressiveness.
The inverse relationship betweenADCvalues and cellular
density is well established by Zelhof et al., suggestive of
increasing diffusion restriction of water protons in adenocar-
cinoma with increasing cellular density and poor differen-
tiation, hence indicating fall in ADC values with increasing
tumor aggressiveness [7].
Earlier, Kim et al. [3] documented that ADC is a useful
tool to differentiate between malignant and benign tissue in
both peripheral and transitional zone based on 3 Tesla phased
array coil study at 0 and 1000 s/mm2 𝑏 values. No correlation
was established between ADC value and Gleason score
of malignant tissue. Similar investigations were performed
by Gibbs et al. [6] and Pickles et al. [5] at 𝑏 values =
0 and 500 s/mm2, only differentiating tumor from normal
peripheral zone.
Later, Yoshimitsu et al. [13] using phased array coil on
1.5 tesla machine and 𝑏 values of 0, 500 and 1000 s/mm2
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(a) (b)
(c)
Figure 3: Patient with high-risk prostate cancer. Pelvic T2W transverse image (a) shows a well-defined low signal intensity region in the
peripheral zone on the left base (arrow). (b) DWI; (c) an ROI drawn on ADC map shows restricted diffusion in corresponding left base PZ,
scored as Gleason 9 on sextant biopsy.
inculcated reverse association between tumor aggressiveness
and ADC value keeping stepwise histopathology as gold
standard on radical prostatectomy specimens. The param-
eters we deployed for our investigation and our results are
somewhat similar to this study; however we used sextant
biopsy histopathology as gold standard. Difference between
well and poorly differentiating carcinomawas also significant
(𝑝 = 0.019) similar to our result (𝑝 < 0.0001).
A recent report by Tamada et al. had similar results to our
study.Their patient cohort of 125 healthymale volunteers and
90 prostate cancer patients was subjected to pelvicMRI using
1.5 Tesla machine, pelvic phased array coil, and maximum 𝑏
value of 800 s/mm2.They found negative correlation between
ADC value and Gleason score of cancer in peripheral zone
proved on core biopsy specimen [8].
In our series of patients, 17 quadrants of biopsy were not
diffusion restricted and 13 out of them had Gleason score
of 6 (76.4%). This finding is explained by Langer et al., who
inferred that sparse tumors had Gleason score of 6, having
more water proton diffusibility and similar ADC values as
adjacent normal peripheral tissue [25]. Tumor visibility and
localization were therefore not improved by T2 combined
with DWI and ADC maps, in cases of well-differentiated
(low-risk) adenocarcinoma [14].
Our results were somewhat similar to Woodfield et al.
[14] although we did not use endorectal coil and identical
𝑏 values for ADC mapping. This infers that appropriate
imaging technique and interpretation of images may give
satisfactory results.
Another recent study by Yag˘ci et al. [15] performed
prospective study in 43 men with 1.5 Tesla MRI, using endo-
rectal coil and maximum 𝑏 value for DWI = 800 s/mm2.
Yag˘ci et al. found negative correlation between ADC value
and histopathology results. They inferred that quantitative
analysis of ADC value may help as a prognostic marker by
indicating degree of tumor differentiation and aggressiveness.
Our results affirm the above mentioned result. A number of
limitations were observed in our study. First is the inclusion
criterion of all biopsy proven cases leading to selection bias.
Second limitation is keeping sextant core biopsy as gold
standard rather than step-section histopathology of radical
prostatectomy specimen. The false negative rate of standard
sextant biopsy is 39% making it less accurate for diagnosis
[26]. Secondly Gleason scoring achieved by transrectal sex-
tant biopsy also undergrades the pathology compared to final
pathological Gleason score of radical specimen and that too
more for low-risk tumors [27].
Thirdly, standard sextant biopsy was used as gold stan-
dard to correlate Gleason score with quantitative ADC values
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Figure 4: Patient with low-risk prostate cancer. Pelvic T2W transverse image (a) shows a well-defined low signal intensity region in the
peripheral zone on the right and left mid zones (arrows). (b) DWI-hyper intense signal in corresponding areas. (c) A radiologist-determined
region of interest on ADC map shows restricted diffusion in right and left peripheral zones, scored as Gleason 6 on sextant biopsy.
on MR. Absolute matching of sextant maps of MRI and
sextant biopsy samples is questionable. Though we only
concentrated on peripheral zone, the sextant mapping of
prostate on MRI and standard sextant biopsy was subjective
and prone to error. Small tumors visible on imaging may be
missed on biopsy sample giving discrepancy in results. We
did not compare the results with final radical prostatectomy
specimen Gleason scores as only 9/28 (32%) patients were
subjected to radical prostatectomy in the study duration.
Also, we used phased array body coil. An endorectal coil
was not employed in this study due to nonavailability in our
institution and secondly it is often not well tolerated. It also
increases susceptibility effects [28]. Central and transitional
zones were not assessed and interobserver variability was
not evaluated. Lastly, there is no general agreement on the
optimal 𝑏 value for DWI of the prostate. The employment
of higher MR field strengths and higher 𝑏 values can refine
tumor detection.
In conclusion, ADC values of prostate carcinoma in
peripheral zone on pelvic MRI performed at 1.5 Tesla,
using phased array body coil and 𝑏 values of 50, 400, and
800 s/mm2, may help to assess aggressiveness of tumor and
may help differentiate between low-risk (Gleason score = 6)
and high-risk (Gleason score = 8 or 9) and intermediate-
risk (Gleason score = 7) and high-risk (Gleason score = 8 or
9) prostate cancer. It may identify patients at higher risk of
recurrence and bad prognosis and help direct their appro-
priate treatment plan. Prospective study with larger sample
size, 𝑏 value of 1000 s/mm2 and keeping radical prostatectomy
specimen as gold standard, needs to be conducted in the
future.
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